nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—osteoarthritis—Prednisone—psoriasis	0.423	1	CpDpCtD
Sulindac—CYP1A1—Clobetasol propionate—psoriasis	0.075	0.207	CbGbCtD
Sulindac—CYP1A1—Methoxsalen—psoriasis	0.0394	0.109	CbGbCtD
Sulindac—ALB—Acitretin—psoriasis	0.0361	0.0996	CbGbCtD
Sulindac—CYP1A2—Clobetasol propionate—psoriasis	0.0335	0.0925	CbGbCtD
Sulindac—PTGS2—Triamcinolone—psoriasis	0.0268	0.074	CbGbCtD
Sulindac—CYP1A1—Cholecalciferol—psoriasis	0.0261	0.072	CbGbCtD
Sulindac—PTGS2—Betamethasone—psoriasis	0.023	0.0634	CbGbCtD
Sulindac—CYP1A2—Methoxsalen—psoriasis	0.0176	0.0486	CbGbCtD
Sulindac—ALB—Mycophenolate mofetil—psoriasis	0.0169	0.0466	CbGbCtD
Sulindac—SLC22A6—Cyclosporine—psoriasis	0.015	0.0415	CbGbCtD
Sulindac—ALB—Prednisone—psoriasis	0.0135	0.0373	CbGbCtD
Sulindac—PTGS2—Dexamethasone—psoriasis	0.0134	0.0369	CbGbCtD
Sulindac—CYP1A1—Dexamethasone—psoriasis	0.0113	0.0312	CbGbCtD
Sulindac—SLC22A6—Methotrexate—psoriasis	0.00796	0.022	CbGbCtD
Sulindac—ALB—Methotrexate—psoriasis	0.00678	0.0187	CbGbCtD
Sulindac—MAPK3—endothelium—psoriasis	0.00285	0.153	CbGeAlD
Sulindac—PTGDR2—tendon—psoriasis	0.00241	0.129	CbGeAlD
Sulindac—PTGS2—skeletal joint—psoriasis	0.0021	0.112	CbGeAlD
Sulindac—PTGS2—synovial membrane of synovial joint—psoriasis	0.00159	0.0854	CbGeAlD
Sulindac—AKR1B1—tendon—psoriasis	0.00128	0.0686	CbGeAlD
Sulindac—MAPK3—skin of body—psoriasis	0.00122	0.0653	CbGeAlD
Sulindac—CYP1A1—skin epidermis—psoriasis	0.00122	0.0652	CbGeAlD
Sulindac—PTGS2—skin epidermis—psoriasis	0.00102	0.0548	CbGeAlD
Sulindac—PPARD—tendon—psoriasis	0.00101	0.0539	CbGeAlD
Sulindac—MAPK3—tendon—psoriasis	0.000928	0.0497	CbGeAlD
Sulindac—PTGS1—endothelium—psoriasis	0.000776	0.0416	CbGeAlD
Sulindac—PTGS2—endothelium—psoriasis	0.000742	0.0397	CbGeAlD
Sulindac—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000458	0.157	CbGdCrCtD
Sulindac—CYP1A1—skin of body—psoriasis	0.000377	0.0202	CbGeAlD
Sulindac—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000366	0.126	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000356	0.122	CbGdCrCtD
Sulindac—PTGS1—skin of body—psoriasis	0.000331	0.0177	CbGeAlD
Sulindac—PTGS2—skin of body—psoriasis	0.000317	0.017	CbGeAlD
Sulindac—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000276	0.0948	CbGdCrCtD
Sulindac—PTGS1—tendon—psoriasis	0.000252	0.0135	CbGeAlD
Sulindac—PTGS2—tendon—psoriasis	0.000241	0.0129	CbGeAlD
Sulindac—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000221	0.076	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000221	0.076	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000215	0.0738	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000167	0.0574	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000167	0.0574	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000163	0.0561	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000101	0.0346	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000101	0.0346	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	9.85e-05	0.0338	CbGdCrCtD
Sulindac—Malaise—Betamethasone—psoriasis	6.95e-05	0.000614	CcSEcCtD
Sulindac—Malaise—Dexamethasone—psoriasis	6.95e-05	0.000614	CcSEcCtD
Sulindac—Oedema—Triamcinolone—psoriasis	6.93e-05	0.000613	CcSEcCtD
Sulindac—Anaphylactic shock—Triamcinolone—psoriasis	6.93e-05	0.000613	CcSEcCtD
Sulindac—Vertigo—Dexamethasone—psoriasis	6.93e-05	0.000612	CcSEcCtD
Sulindac—Vertigo—Betamethasone—psoriasis	6.93e-05	0.000612	CcSEcCtD
Sulindac—Syncope—Dexamethasone—psoriasis	6.91e-05	0.000611	CcSEcCtD
Sulindac—Syncope—Betamethasone—psoriasis	6.91e-05	0.000611	CcSEcCtD
Sulindac—Constipation—Mycophenolate mofetil—psoriasis	6.91e-05	0.000611	CcSEcCtD
Sulindac—Arrhythmia—Prednisone—psoriasis	6.89e-05	0.000609	CcSEcCtD
Sulindac—Sweating—Methotrexate—psoriasis	6.88e-05	0.000608	CcSEcCtD
Sulindac—Hypotension—Hydrocortisone—psoriasis	6.88e-05	0.000608	CcSEcCtD
Sulindac—Haematuria—Methotrexate—psoriasis	6.85e-05	0.000605	CcSEcCtD
Sulindac—Feeling abnormal—Cyclosporine—psoriasis	6.83e-05	0.000604	CcSEcCtD
Sulindac—Shock—Triamcinolone—psoriasis	6.82e-05	0.000603	CcSEcCtD
Sulindac—Insomnia—Prednisolone—psoriasis	6.82e-05	0.000603	CcSEcCtD
Sulindac—Alopecia—Prednisone—psoriasis	6.82e-05	0.000602	CcSEcCtD
Sulindac—Gastrointestinal pain—Cyclosporine—psoriasis	6.78e-05	0.000599	CcSEcCtD
Sulindac—Loss of consciousness—Dexamethasone—psoriasis	6.78e-05	0.000599	CcSEcCtD
Sulindac—Loss of consciousness—Betamethasone—psoriasis	6.78e-05	0.000599	CcSEcCtD
Sulindac—Dizziness—Mycophenolic acid—psoriasis	6.77e-05	0.000599	CcSEcCtD
Sulindac—Epistaxis—Methotrexate—psoriasis	6.77e-05	0.000599	CcSEcCtD
Sulindac—Paraesthesia—Prednisolone—psoriasis	6.77e-05	0.000598	CcSEcCtD
Sulindac—Tachycardia—Triamcinolone—psoriasis	6.77e-05	0.000598	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Hydrocortisone—psoriasis	6.71e-05	0.000593	CcSEcCtD
Sulindac—Hyperhidrosis—Triamcinolone—psoriasis	6.7e-05	0.000592	CcSEcCtD
Sulindac—Agranulocytosis—Methotrexate—psoriasis	6.7e-05	0.000592	CcSEcCtD
Sulindac—Convulsion—Dexamethasone—psoriasis	6.68e-05	0.00059	CcSEcCtD
Sulindac—Convulsion—Betamethasone—psoriasis	6.68e-05	0.00059	CcSEcCtD
Sulindac—Feeling abnormal—Mycophenolate mofetil—psoriasis	6.66e-05	0.000589	CcSEcCtD
Sulindac—Insomnia—Hydrocortisone—psoriasis	6.66e-05	0.000589	CcSEcCtD
Sulindac—Hypertension—Betamethasone—psoriasis	6.66e-05	0.000588	CcSEcCtD
Sulindac—Hypertension—Dexamethasone—psoriasis	6.66e-05	0.000588	CcSEcCtD
Sulindac—Paraesthesia—Hydrocortisone—psoriasis	6.61e-05	0.000584	CcSEcCtD
Sulindac—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.61e-05	0.000584	CcSEcCtD
Sulindac—Urticaria—Cyclosporine—psoriasis	6.58e-05	0.000582	CcSEcCtD
Sulindac—Myalgia—Dexamethasone—psoriasis	6.56e-05	0.00058	CcSEcCtD
Sulindac—Myalgia—Betamethasone—psoriasis	6.56e-05	0.00058	CcSEcCtD
Sulindac—Body temperature increased—Cyclosporine—psoriasis	6.55e-05	0.000579	CcSEcCtD
Sulindac—Vomiting—Mycophenolic acid—psoriasis	6.51e-05	0.000576	CcSEcCtD
Sulindac—Discomfort—Betamethasone—psoriasis	6.49e-05	0.000573	CcSEcCtD
Sulindac—Discomfort—Dexamethasone—psoriasis	6.49e-05	0.000573	CcSEcCtD
Sulindac—Dyspepsia—Hydrocortisone—psoriasis	6.48e-05	0.000573	CcSEcCtD
Sulindac—Rash—Mycophenolic acid—psoriasis	6.46e-05	0.000571	CcSEcCtD
Sulindac—Dermatitis—Mycophenolic acid—psoriasis	6.45e-05	0.00057	CcSEcCtD
Sulindac—Hepatitis—Methotrexate—psoriasis	6.45e-05	0.00057	CcSEcCtD
Sulindac—Urticaria—Mycophenolate mofetil—psoriasis	6.42e-05	0.000568	CcSEcCtD
Sulindac—Headache—Mycophenolic acid—psoriasis	6.42e-05	0.000567	CcSEcCtD
Sulindac—Decreased appetite—Hydrocortisone—psoriasis	6.4e-05	0.000566	CcSEcCtD
Sulindac—Body temperature increased—Mycophenolate mofetil—psoriasis	6.39e-05	0.000565	CcSEcCtD
Sulindac—Fatigue—Hydrocortisone—psoriasis	6.35e-05	0.000561	CcSEcCtD
Sulindac—Vision blurred—Prednisone—psoriasis	6.33e-05	0.000559	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.32e-05	0.000558	CcSEcCtD
Sulindac—Anaphylactic shock—Dexamethasone—psoriasis	6.29e-05	0.000556	CcSEcCtD
Sulindac—Oedema—Betamethasone—psoriasis	6.29e-05	0.000556	CcSEcCtD
Sulindac—Anaphylactic shock—Betamethasone—psoriasis	6.29e-05	0.000556	CcSEcCtD
Sulindac—Oedema—Dexamethasone—psoriasis	6.29e-05	0.000556	CcSEcCtD
Sulindac—Insomnia—Triamcinolone—psoriasis	6.27e-05	0.000554	CcSEcCtD
Sulindac—Ill-defined disorder—Prednisone—psoriasis	6.23e-05	0.000551	CcSEcCtD
Sulindac—Paraesthesia—Triamcinolone—psoriasis	6.23e-05	0.00055	CcSEcCtD
Sulindac—Feeling abnormal—Prednisolone—psoriasis	6.21e-05	0.000549	CcSEcCtD
Sulindac—Visual impairment—Methotrexate—psoriasis	6.21e-05	0.000549	CcSEcCtD
Sulindac—Anaemia—Prednisone—psoriasis	6.21e-05	0.000548	CcSEcCtD
Sulindac—Shock—Betamethasone—psoriasis	6.19e-05	0.000547	CcSEcCtD
Sulindac—Shock—Dexamethasone—psoriasis	6.19e-05	0.000547	CcSEcCtD
Sulindac—Dyspnoea—Triamcinolone—psoriasis	6.18e-05	0.000546	CcSEcCtD
Sulindac—Thrombocytopenia—Dexamethasone—psoriasis	6.16e-05	0.000544	CcSEcCtD
Sulindac—Thrombocytopenia—Betamethasone—psoriasis	6.16e-05	0.000544	CcSEcCtD
Sulindac—Tachycardia—Dexamethasone—psoriasis	6.14e-05	0.000543	CcSEcCtD
Sulindac—Tachycardia—Betamethasone—psoriasis	6.14e-05	0.000543	CcSEcCtD
Sulindac—Angioedema—Prednisone—psoriasis	6.14e-05	0.000542	CcSEcCtD
Sulindac—Hypersensitivity—Cyclosporine—psoriasis	6.11e-05	0.00054	CcSEcCtD
Sulindac—Dyspepsia—Triamcinolone—psoriasis	6.1e-05	0.00054	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—psoriasis	6.09e-05	0.000539	CcSEcCtD
Sulindac—Nausea—Mycophenolic acid—psoriasis	6.08e-05	0.000538	CcSEcCtD
Sulindac—Hyperhidrosis—Betamethasone—psoriasis	6.08e-05	0.000538	CcSEcCtD
Sulindac—Hyperhidrosis—Dexamethasone—psoriasis	6.08e-05	0.000538	CcSEcCtD
Sulindac—Feeling abnormal—Hydrocortisone—psoriasis	6.07e-05	0.000536	CcSEcCtD
Sulindac—Malaise—Prednisone—psoriasis	6.06e-05	0.000535	CcSEcCtD
Sulindac—Vertigo—Prednisone—psoriasis	6.03e-05	0.000533	CcSEcCtD
Sulindac—Gastrointestinal pain—Hydrocortisone—psoriasis	6.02e-05	0.000532	CcSEcCtD
Sulindac—Syncope—Prednisone—psoriasis	6.02e-05	0.000532	CcSEcCtD
Sulindac—Tinnitus—Methotrexate—psoriasis	6.01e-05	0.000531	CcSEcCtD
Sulindac—Anorexia—Dexamethasone—psoriasis	6e-05	0.00053	CcSEcCtD
Sulindac—Anorexia—Betamethasone—psoriasis	6e-05	0.00053	CcSEcCtD
Sulindac—Urticaria—Prednisolone—psoriasis	5.99e-05	0.000529	CcSEcCtD
Sulindac—Fatigue—Triamcinolone—psoriasis	5.98e-05	0.000528	CcSEcCtD
Sulindac—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.96e-05	0.000526	CcSEcCtD
Sulindac—Asthenia—Cyclosporine—psoriasis	5.95e-05	0.000525	CcSEcCtD
Sulindac—Loss of consciousness—Prednisone—psoriasis	5.9e-05	0.000522	CcSEcCtD
Sulindac—Hypotension—Dexamethasone—psoriasis	5.88e-05	0.00052	CcSEcCtD
Sulindac—Hypotension—Betamethasone—psoriasis	5.88e-05	0.00052	CcSEcCtD
Sulindac—Pruritus—Cyclosporine—psoriasis	5.86e-05	0.000518	CcSEcCtD
Sulindac—Urticaria—Hydrocortisone—psoriasis	5.85e-05	0.000517	CcSEcCtD
Sulindac—Body temperature increased—Hydrocortisone—psoriasis	5.82e-05	0.000515	CcSEcCtD
Sulindac—Convulsion—Prednisone—psoriasis	5.82e-05	0.000514	CcSEcCtD
Sulindac—Asthenia—Mycophenolate mofetil—psoriasis	5.8e-05	0.000513	CcSEcCtD
Sulindac—Hypertension—Prednisone—psoriasis	5.8e-05	0.000512	CcSEcCtD
Sulindac—Chills—Methotrexate—psoriasis	5.78e-05	0.000511	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Betamethasone—psoriasis	5.73e-05	0.000507	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.73e-05	0.000507	CcSEcCtD
Sulindac—Pruritus—Mycophenolate mofetil—psoriasis	5.72e-05	0.000505	CcSEcCtD
Sulindac—Myalgia—Prednisone—psoriasis	5.72e-05	0.000505	CcSEcCtD
Sulindac—Arthralgia—Prednisone—psoriasis	5.72e-05	0.000505	CcSEcCtD
Sulindac—Feeling abnormal—Triamcinolone—psoriasis	5.71e-05	0.000505	CcSEcCtD
Sulindac—Alopecia—Methotrexate—psoriasis	5.7e-05	0.000503	CcSEcCtD
Sulindac—Insomnia—Betamethasone—psoriasis	5.69e-05	0.000503	CcSEcCtD
Sulindac—Insomnia—Dexamethasone—psoriasis	5.69e-05	0.000503	CcSEcCtD
Sulindac—Diarrhoea—Cyclosporine—psoriasis	5.67e-05	0.000501	CcSEcCtD
Sulindac—Paraesthesia—Betamethasone—psoriasis	5.65e-05	0.000499	CcSEcCtD
Sulindac—Paraesthesia—Dexamethasone—psoriasis	5.65e-05	0.000499	CcSEcCtD
Sulindac—Discomfort—Prednisone—psoriasis	5.65e-05	0.000499	CcSEcCtD
Sulindac—Hypersensitivity—Prednisolone—psoriasis	5.56e-05	0.000491	CcSEcCtD
Sulindac—Dyspepsia—Dexamethasone—psoriasis	5.54e-05	0.00049	CcSEcCtD
Sulindac—Dyspepsia—Betamethasone—psoriasis	5.54e-05	0.00049	CcSEcCtD
Sulindac—Diarrhoea—Mycophenolate mofetil—psoriasis	5.53e-05	0.000489	CcSEcCtD
Sulindac—Urticaria—Triamcinolone—psoriasis	5.51e-05	0.000487	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—psoriasis	5.5e-05	0.000486	CcSEcCtD
Sulindac—Body temperature increased—Triamcinolone—psoriasis	5.48e-05	0.000484	CcSEcCtD
Sulindac—Dizziness—Cyclosporine—psoriasis	5.48e-05	0.000484	CcSEcCtD
Sulindac—Anaphylactic shock—Prednisone—psoriasis	5.48e-05	0.000484	CcSEcCtD
Sulindac—Oedema—Prednisone—psoriasis	5.48e-05	0.000484	CcSEcCtD
Sulindac—Decreased appetite—Betamethasone—psoriasis	5.47e-05	0.000483	CcSEcCtD
Sulindac—Decreased appetite—Dexamethasone—psoriasis	5.47e-05	0.000483	CcSEcCtD
Sulindac—Hypersensitivity—Hydrocortisone—psoriasis	5.43e-05	0.00048	CcSEcCtD
Sulindac—Fatigue—Betamethasone—psoriasis	5.43e-05	0.000479	CcSEcCtD
Sulindac—Fatigue—Dexamethasone—psoriasis	5.43e-05	0.000479	CcSEcCtD
Sulindac—Shock—Prednisone—psoriasis	5.39e-05	0.000476	CcSEcCtD
Sulindac—Tachycardia—Prednisone—psoriasis	5.35e-05	0.000473	CcSEcCtD
Sulindac—Dizziness—Mycophenolate mofetil—psoriasis	5.35e-05	0.000472	CcSEcCtD
Sulindac—Hyperhidrosis—Prednisone—psoriasis	5.3e-05	0.000468	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—psoriasis	5.29e-05	0.000467	CcSEcCtD
Sulindac—Asthenia—Hydrocortisone—psoriasis	5.28e-05	0.000467	CcSEcCtD
Sulindac—Vomiting—Cyclosporine—psoriasis	5.27e-05	0.000466	CcSEcCtD
Sulindac—Rash—Cyclosporine—psoriasis	5.23e-05	0.000462	CcSEcCtD
Sulindac—Anorexia—Prednisone—psoriasis	5.22e-05	0.000462	CcSEcCtD
Sulindac—Dermatitis—Cyclosporine—psoriasis	5.22e-05	0.000461	CcSEcCtD
Sulindac—Pruritus—Hydrocortisone—psoriasis	5.21e-05	0.000461	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—psoriasis	5.21e-05	0.00046	CcSEcCtD
Sulindac—Headache—Cyclosporine—psoriasis	5.19e-05	0.000459	CcSEcCtD
Sulindac—Anaemia—Methotrexate—psoriasis	5.19e-05	0.000458	CcSEcCtD
Sulindac—Feeling abnormal—Dexamethasone—psoriasis	5.19e-05	0.000458	CcSEcCtD
Sulindac—Feeling abnormal—Betamethasone—psoriasis	5.19e-05	0.000458	CcSEcCtD
Sulindac—Gastrointestinal pain—Betamethasone—psoriasis	5.15e-05	0.000455	CcSEcCtD
Sulindac—Gastrointestinal pain—Dexamethasone—psoriasis	5.15e-05	0.000455	CcSEcCtD
Sulindac—Vomiting—Mycophenolate mofetil—psoriasis	5.14e-05	0.000454	CcSEcCtD
Sulindac—Hypersensitivity—Triamcinolone—psoriasis	5.11e-05	0.000452	CcSEcCtD
Sulindac—Rash—Mycophenolate mofetil—psoriasis	5.1e-05	0.00045	CcSEcCtD
Sulindac—Dermatitis—Mycophenolate mofetil—psoriasis	5.09e-05	0.00045	CcSEcCtD
Sulindac—Headache—Mycophenolate mofetil—psoriasis	5.06e-05	0.000448	CcSEcCtD
Sulindac—Malaise—Methotrexate—psoriasis	5.06e-05	0.000447	CcSEcCtD
Sulindac—Vertigo—Methotrexate—psoriasis	5.04e-05	0.000446	CcSEcCtD
Sulindac—Diarrhoea—Hydrocortisone—psoriasis	5.04e-05	0.000445	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—psoriasis	5.02e-05	0.000444	CcSEcCtD
Sulindac—Urticaria—Dexamethasone—psoriasis	5e-05	0.000442	CcSEcCtD
Sulindac—Urticaria—Betamethasone—psoriasis	5e-05	0.000442	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Prednisone—psoriasis	4.99e-05	0.000441	CcSEcCtD
Sulindac—Dizziness—Prednisolone—psoriasis	4.99e-05	0.000441	CcSEcCtD
Sulindac—Asthenia—Triamcinolone—psoriasis	4.98e-05	0.00044	CcSEcCtD
Sulindac—Body temperature increased—Betamethasone—psoriasis	4.97e-05	0.00044	CcSEcCtD
Sulindac—Body temperature increased—Dexamethasone—psoriasis	4.97e-05	0.00044	CcSEcCtD
Sulindac—Insomnia—Prednisone—psoriasis	4.96e-05	0.000438	CcSEcCtD
Sulindac—Nausea—Cyclosporine—psoriasis	4.92e-05	0.000435	CcSEcCtD
Sulindac—Paraesthesia—Prednisone—psoriasis	4.92e-05	0.000435	CcSEcCtD
Sulindac—Pruritus—Triamcinolone—psoriasis	4.91e-05	0.000434	CcSEcCtD
Sulindac—Dizziness—Hydrocortisone—psoriasis	4.87e-05	0.00043	CcSEcCtD
Sulindac—Convulsion—Methotrexate—psoriasis	4.86e-05	0.00043	CcSEcCtD
Sulindac—Dyspepsia—Prednisone—psoriasis	4.82e-05	0.000426	CcSEcCtD
Sulindac—Nausea—Mycophenolate mofetil—psoriasis	4.8e-05	0.000424	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—psoriasis	4.78e-05	0.000422	CcSEcCtD
Sulindac—Chest pain—Methotrexate—psoriasis	4.78e-05	0.000422	CcSEcCtD
Sulindac—Myalgia—Methotrexate—psoriasis	4.78e-05	0.000422	CcSEcCtD
Sulindac—Decreased appetite—Prednisone—psoriasis	4.76e-05	0.000421	CcSEcCtD
Sulindac—Rash—Prednisolone—psoriasis	4.75e-05	0.00042	CcSEcCtD
Sulindac—Dermatitis—Prednisolone—psoriasis	4.75e-05	0.00042	CcSEcCtD
Sulindac—Fatigue—Prednisone—psoriasis	4.72e-05	0.000418	CcSEcCtD
Sulindac—Headache—Prednisolone—psoriasis	4.72e-05	0.000418	CcSEcCtD
Sulindac—Discomfort—Methotrexate—psoriasis	4.72e-05	0.000417	CcSEcCtD
Sulindac—Constipation—Prednisone—psoriasis	4.69e-05	0.000414	CcSEcCtD
Sulindac—Vomiting—Hydrocortisone—psoriasis	4.68e-05	0.000414	CcSEcCtD
Sulindac—Rash—Hydrocortisone—psoriasis	4.64e-05	0.00041	CcSEcCtD
Sulindac—Dermatitis—Hydrocortisone—psoriasis	4.64e-05	0.00041	CcSEcCtD
Sulindac—Headache—Hydrocortisone—psoriasis	4.61e-05	0.000408	CcSEcCtD
Sulindac—Dizziness—Triamcinolone—psoriasis	4.59e-05	0.000405	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—psoriasis	4.58e-05	0.000405	CcSEcCtD
Sulindac—Feeling abnormal—Prednisone—psoriasis	4.52e-05	0.000399	CcSEcCtD
Sulindac—Asthenia—Dexamethasone—psoriasis	4.51e-05	0.000399	CcSEcCtD
Sulindac—Asthenia—Betamethasone—psoriasis	4.51e-05	0.000399	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—psoriasis	4.48e-05	0.000396	CcSEcCtD
Sulindac—Gastrointestinal pain—Prednisone—psoriasis	4.48e-05	0.000396	CcSEcCtD
Sulindac—Nausea—Prednisolone—psoriasis	4.48e-05	0.000396	CcSEcCtD
Sulindac—Pruritus—Dexamethasone—psoriasis	4.45e-05	0.000393	CcSEcCtD
Sulindac—Pruritus—Betamethasone—psoriasis	4.45e-05	0.000393	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—psoriasis	4.43e-05	0.000391	CcSEcCtD
Sulindac—Vomiting—Triamcinolone—psoriasis	4.41e-05	0.00039	CcSEcCtD
Sulindac—Nausea—Hydrocortisone—psoriasis	4.37e-05	0.000387	CcSEcCtD
Sulindac—Rash—Triamcinolone—psoriasis	4.37e-05	0.000386	CcSEcCtD
Sulindac—Dermatitis—Triamcinolone—psoriasis	4.37e-05	0.000386	CcSEcCtD
Sulindac—Anorexia—Methotrexate—psoriasis	4.37e-05	0.000386	CcSEcCtD
Sulindac—Urticaria—Prednisone—psoriasis	4.35e-05	0.000385	CcSEcCtD
Sulindac—Headache—Triamcinolone—psoriasis	4.34e-05	0.000384	CcSEcCtD
Sulindac—Body temperature increased—Prednisone—psoriasis	4.33e-05	0.000383	CcSEcCtD
Sulindac—Diarrhoea—Betamethasone—psoriasis	4.31e-05	0.00038	CcSEcCtD
Sulindac—Diarrhoea—Dexamethasone—psoriasis	4.31e-05	0.00038	CcSEcCtD
Sulindac—Hypotension—Methotrexate—psoriasis	4.28e-05	0.000378	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methotrexate—psoriasis	4.17e-05	0.000369	CcSEcCtD
Sulindac—Dizziness—Dexamethasone—psoriasis	4.16e-05	0.000368	CcSEcCtD
Sulindac—Dizziness—Betamethasone—psoriasis	4.16e-05	0.000368	CcSEcCtD
Sulindac—Insomnia—Methotrexate—psoriasis	4.14e-05	0.000366	CcSEcCtD
Sulindac—Nausea—Triamcinolone—psoriasis	4.12e-05	0.000364	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—psoriasis	4.11e-05	0.000363	CcSEcCtD
Sulindac—Dyspnoea—Methotrexate—psoriasis	4.08e-05	0.000361	CcSEcCtD
Sulindac—Somnolence—Methotrexate—psoriasis	4.07e-05	0.00036	CcSEcCtD
Sulindac—Hypersensitivity—Prednisone—psoriasis	4.04e-05	0.000357	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—psoriasis	4.03e-05	0.000356	CcSEcCtD
Sulindac—Vomiting—Betamethasone—psoriasis	4e-05	0.000354	CcSEcCtD
Sulindac—Vomiting—Dexamethasone—psoriasis	4e-05	0.000354	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—psoriasis	3.98e-05	0.000352	CcSEcCtD
Sulindac—Rash—Betamethasone—psoriasis	3.97e-05	0.000351	CcSEcCtD
Sulindac—Rash—Dexamethasone—psoriasis	3.97e-05	0.000351	CcSEcCtD
Sulindac—Dermatitis—Betamethasone—psoriasis	3.96e-05	0.00035	CcSEcCtD
Sulindac—Dermatitis—Dexamethasone—psoriasis	3.96e-05	0.00035	CcSEcCtD
Sulindac—Fatigue—Methotrexate—psoriasis	3.95e-05	0.000349	CcSEcCtD
Sulindac—Headache—Betamethasone—psoriasis	3.94e-05	0.000348	CcSEcCtD
Sulindac—Headache—Dexamethasone—psoriasis	3.94e-05	0.000348	CcSEcCtD
Sulindac—Asthenia—Prednisone—psoriasis	3.93e-05	0.000347	CcSEcCtD
Sulindac—Pruritus—Prednisone—psoriasis	3.88e-05	0.000343	CcSEcCtD
Sulindac—MAPK3—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	3.8e-05	0.000475	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	3.8e-05	0.000474	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	3.8e-05	0.000474	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.78e-05	0.000472	CbGpPWpGaD
Sulindac—Feeling abnormal—Methotrexate—psoriasis	3.77e-05	0.000334	CcSEcCtD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.75e-05	0.000468	CbGpPWpGaD
Sulindac—Diarrhoea—Prednisone—psoriasis	3.75e-05	0.000331	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—psoriasis	3.74e-05	0.000331	CcSEcCtD
Sulindac—MAPK3—Signaling by GPCR—CCL20—psoriasis	3.74e-05	0.000467	CbGpPWpGaD
Sulindac—Nausea—Betamethasone—psoriasis	3.74e-05	0.00033	CcSEcCtD
Sulindac—Nausea—Dexamethasone—psoriasis	3.74e-05	0.00033	CcSEcCtD
Sulindac—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.72e-05	0.000465	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—TNF—psoriasis	3.7e-05	0.000462	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IFNG—psoriasis	3.69e-05	0.000461	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TAGAP—psoriasis	3.69e-05	0.000461	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	3.65e-05	0.000456	CbGpPWpGaD
Sulindac—MAPK3—MyD88-independent cascade—IL6—psoriasis	3.65e-05	0.000455	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—JUN—psoriasis	3.65e-05	0.000455	CbGpPWpGaD
Sulindac—Urticaria—Methotrexate—psoriasis	3.64e-05	0.000322	CcSEcCtD
Sulindac—Dizziness—Prednisone—psoriasis	3.62e-05	0.00032	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—psoriasis	3.62e-05	0.00032	CcSEcCtD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.61e-05	0.000451	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IFNG—psoriasis	3.61e-05	0.000451	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.57e-05	0.000446	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—IL6—psoriasis	3.56e-05	0.000445	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—STAT3—psoriasis	3.54e-05	0.000442	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—CXCL8—psoriasis	3.52e-05	0.00044	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—NFKB1—psoriasis	3.51e-05	0.000438	CbGpPWpGaD
Sulindac—Vomiting—Prednisone—psoriasis	3.48e-05	0.000308	CcSEcCtD
Sulindac—MAPK3—Senescence-Associated Secretory Phenotype (SASP)—IL6—psoriasis	3.48e-05	0.000435	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—TP53—psoriasis	3.47e-05	0.000432	CbGpPWpGaD
Sulindac—Rash—Prednisone—psoriasis	3.46e-05	0.000305	CcSEcCtD
Sulindac—Dermatitis—Prednisone—psoriasis	3.45e-05	0.000305	CcSEcCtD
Sulindac—PTGS1—Metabolism—CYP2S1—psoriasis	3.45e-05	0.00043	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	3.45e-05	0.00043	CbGpPWpGaD
Sulindac—MAPK3—Oxidative Stress Induced Senescence—TP53—psoriasis	3.44e-05	0.000429	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.44e-05	0.000429	CbGpPWpGaD
Sulindac—Headache—Prednisone—psoriasis	3.43e-05	0.000303	CcSEcCtD
Sulindac—MAPK3—VEGFA-VEGFR2 Pathway—IL6—psoriasis	3.43e-05	0.000428	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL6—psoriasis	3.4e-05	0.000425	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—VDR—psoriasis	3.38e-05	0.000422	CbGpPWpGaD
Sulindac—Hypersensitivity—Methotrexate—psoriasis	3.37e-05	0.000298	CcSEcCtD
Sulindac—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	3.36e-05	0.000419	CbGpPWpGaD
Sulindac—Asthenia—Methotrexate—psoriasis	3.29e-05	0.00029	CcSEcCtD
Sulindac—MAPK3—Activated TLR4 signalling—IL6—psoriasis	3.28e-05	0.00041	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—STAT3—psoriasis	3.28e-05	0.00041	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.28e-05	0.000409	CbGpPWpGaD
Sulindac—Nausea—Prednisone—psoriasis	3.25e-05	0.000288	CcSEcCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—TYK2—psoriasis	3.25e-05	0.000405	CbGpPWpGaD
Sulindac—Pruritus—Methotrexate—psoriasis	3.24e-05	0.000286	CcSEcCtD
Sulindac—MAPK3—Signaling by VEGF—IL6—psoriasis	3.24e-05	0.000404	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—SOCS1—psoriasis	3.23e-05	0.000404	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NDUFA5—psoriasis	3.22e-05	0.000402	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Insulin receptor—IL6—psoriasis	3.22e-05	0.000401	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—STAT3—psoriasis	3.21e-05	0.000401	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.2e-05	0.0004	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—TYK2—psoriasis	3.19e-05	0.000399	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IL6—psoriasis	3.17e-05	0.000396	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ITGAL—psoriasis	3.16e-05	0.000394	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—STAT3—psoriasis	3.16e-05	0.000394	CbGpPWpGaD
Sulindac—Diarrhoea—Methotrexate—psoriasis	3.13e-05	0.000277	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—APOE—psoriasis	3.13e-05	0.000391	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—LEP—psoriasis	3.13e-05	0.000391	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.12e-05	0.000389	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—PCNA—psoriasis	3.1e-05	0.000387	CbGpPWpGaD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	3.09e-05	0.000385	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	3.07e-05	0.000384	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IFNG—psoriasis	3.04e-05	0.00038	CbGpPWpGaD
Sulindac—Dizziness—Methotrexate—psoriasis	3.03e-05	0.000268	CcSEcCtD
Sulindac—ALB—Platelet degranulation—VEGFA—psoriasis	3.01e-05	0.000376	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TNF—psoriasis	3.01e-05	0.000376	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	3e-05	0.000375	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3e-05	0.000375	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.99e-05	0.000373	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—CXCL8—psoriasis	2.96e-05	0.00037	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TNF—psoriasis	2.96e-05	0.00037	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	2.96e-05	0.000369	CbGpPWpGaD
Sulindac—MAPK3—Immune System—REL—psoriasis	2.95e-05	0.000368	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NFKBIA—psoriasis	2.92e-05	0.000364	CbGpPWpGaD
Sulindac—Vomiting—Methotrexate—psoriasis	2.91e-05	0.000257	CcSEcCtD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	2.91e-05	0.000363	CbGpPWpGaD
Sulindac—ALB—Hemostasis—ITGAL—psoriasis	2.9e-05	0.000361	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—CARM1—psoriasis	2.89e-05	0.000361	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—TYK2—psoriasis	2.89e-05	0.000361	CbGpPWpGaD
Sulindac—Rash—Methotrexate—psoriasis	2.89e-05	0.000255	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—psoriasis	2.88e-05	0.000255	CcSEcCtD
Sulindac—Headache—Methotrexate—psoriasis	2.87e-05	0.000254	CcSEcCtD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.87e-05	0.000358	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFIH1—psoriasis	2.87e-05	0.000358	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NDUFA5—psoriasis	2.86e-05	0.000357	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.81e-05	0.000351	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.81e-05	0.000351	CbGpPWpGaD
Sulindac—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	2.79e-05	0.000348	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	2.78e-05	0.000347	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.78e-05	0.000346	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—PCNA—psoriasis	2.77e-05	0.000346	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HLA-B—psoriasis	2.76e-05	0.000344	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—JUN—psoriasis	2.76e-05	0.000344	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—IL6—psoriasis	2.75e-05	0.000343	CbGpPWpGaD
Sulindac—MAPK3—Toll-Like Receptors Cascades—IL6—psoriasis	2.75e-05	0.000343	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP2S1—psoriasis	2.74e-05	0.000342	CbGpPWpGaD
Sulindac—Nausea—Methotrexate—psoriasis	2.72e-05	0.00024	CcSEcCtD
Sulindac—MAPK3—Immune System—HLA-C—psoriasis	2.72e-05	0.000339	CbGpPWpGaD
Sulindac—PPARD—Metabolism—CAT—psoriasis	2.71e-05	0.000338	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—LEP—psoriasis	2.7e-05	0.000337	CbGpPWpGaD
Sulindac—MAPK3—Immune System—TNFAIP3—psoriasis	2.68e-05	0.000335	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.67e-05	0.000334	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.67e-05	0.000333	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TP53—psoriasis	2.65e-05	0.000331	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—NFKB1—psoriasis	2.65e-05	0.000331	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—IL6—psoriasis	2.63e-05	0.000328	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TP53—psoriasis	2.61e-05	0.000326	CbGpPWpGaD
Sulindac—ALB—Metabolism—NDUFA5—psoriasis	2.61e-05	0.000325	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—IL6—psoriasis	2.59e-05	0.000323	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—NFKB1—psoriasis	2.53e-05	0.000316	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—NFKB1—psoriasis	2.49e-05	0.000311	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—IL6—psoriasis	2.47e-05	0.000309	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NOS2—psoriasis	2.47e-05	0.000308	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—IL6—psoriasis	2.46e-05	0.000307	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—IL6—psoriasis	2.45e-05	0.000306	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CRP—psoriasis	2.44e-05	0.000304	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—IL6—psoriasis	2.44e-05	0.000304	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP2S1—psoriasis	2.43e-05	0.000303	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.43e-05	0.000303	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IL6—psoriasis	2.43e-05	0.000303	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—CP—psoriasis	2.42e-05	0.000302	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—VEGFA—psoriasis	2.41e-05	0.0003	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—TP53—psoriasis	2.41e-05	0.0003	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—TNF—psoriasis	2.39e-05	0.000298	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TYK2—psoriasis	2.39e-05	0.000298	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	2.39e-05	0.000298	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—STAT3—psoriasis	2.38e-05	0.000298	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—PPARG—psoriasis	2.36e-05	0.000294	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.36e-05	0.000294	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—PPARG—psoriasis	2.35e-05	0.000294	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TNF—psoriasis	2.34e-05	0.000292	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	2.31e-05	0.000288	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.29e-05	0.000286	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—IL6—psoriasis	2.29e-05	0.000286	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—IL6—psoriasis	2.29e-05	0.000286	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—STAT3—psoriasis	2.27e-05	0.000284	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—IL6—psoriasis	2.27e-05	0.000284	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-E—psoriasis	2.26e-05	0.000281	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—IL6—psoriasis	2.25e-05	0.000281	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—IL6—psoriasis	2.24e-05	0.00028	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—STAT3—psoriasis	2.24e-05	0.000279	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NFKBIA—psoriasis	2.22e-05	0.000278	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP2S1—psoriasis	2.22e-05	0.000276	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL20—psoriasis	2.21e-05	0.000276	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—IL6—psoriasis	2.2e-05	0.000275	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.12e-05	0.000265	CbGpPWpGaD
Sulindac—PPARD—Metabolism—APOE—psoriasis	2.11e-05	0.000263	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CXCL8—psoriasis	2.08e-05	0.00026	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TYK2—psoriasis	2.06e-05	0.000257	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—psoriasis	2.06e-05	0.000257	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.04e-05	0.000255	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—VEGFA—psoriasis	2.04e-05	0.000255	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.03e-05	0.000253	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—IL6—psoriasis	1.98e-05	0.000247	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.96e-05	0.000245	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—JUN—psoriasis	1.93e-05	0.000241	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.93e-05	0.000241	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.89e-05	0.000235	CbGpPWpGaD
Sulindac—MAPK3—Immune System—SOCS1—psoriasis	1.88e-05	0.000235	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NFKB1—psoriasis	1.86e-05	0.000232	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.86e-05	0.000231	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PPARG—psoriasis	1.83e-05	0.000229	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NDUFA5—psoriasis	1.82e-05	0.000227	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—TYK2—psoriasis	1.82e-05	0.000227	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—psoriasis	1.82e-05	0.000227	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.81e-05	0.000226	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—VDR—psoriasis	1.73e-05	0.000216	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.7e-05	0.000212	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—VEGFA—psoriasis	1.69e-05	0.000211	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CARM1—psoriasis	1.68e-05	0.00021	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—STAT3—psoriasis	1.67e-05	0.000209	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD8A—psoriasis	1.67e-05	0.000208	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—IL6—psoriasis	1.67e-05	0.000208	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CD4—psoriasis	1.65e-05	0.000206	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—NFKB1—psoriasis	1.61e-05	0.000201	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-B—psoriasis	1.61e-05	0.000201	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.59e-05	0.000198	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL6—psoriasis	1.59e-05	0.000198	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.57e-05	0.000197	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—IL6—psoriasis	1.56e-05	0.000195	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2S1—psoriasis	1.55e-05	0.000193	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-A—psoriasis	1.49e-05	0.000186	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—JUN—psoriasis	1.47e-05	0.000184	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—VEGFA—psoriasis	1.46e-05	0.000182	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—STAT3—psoriasis	1.44e-05	0.00018	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.44e-05	0.000179	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—VEGFA—psoriasis	1.43e-05	0.000179	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CRP—psoriasis	1.42e-05	0.000177	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NFKB1—psoriasis	1.42e-05	0.000177	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—IL6—psoriasis	1.41e-05	0.000176	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.4e-05	0.000175	CbGpPWpGaD
Sulindac—MAPK3—Disease—HLA-A—psoriasis	1.37e-05	0.000172	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DRB1—psoriasis	1.36e-05	0.00017	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CARM1—psoriasis	1.34e-05	0.000167	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.34e-05	0.000167	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ICAM1—psoriasis	1.31e-05	0.000163	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NFKBIA—psoriasis	1.3e-05	0.000162	CbGpPWpGaD
Sulindac—MAPK3—Disease—APOE—psoriasis	1.28e-05	0.00016	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—psoriasis	1.28e-05	0.000159	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.27e-05	0.000159	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.25e-05	0.000156	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TNF—psoriasis	1.25e-05	0.000156	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SOCS1—psoriasis	1.22e-05	0.000152	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—PPARG—psoriasis	1.2e-05	0.00015	CbGpPWpGaD
Sulindac—MAPK3—Disease—NOS2—psoriasis	1.2e-05	0.000149	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NOS2—psoriasis	1.19e-05	0.000148	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CARM1—psoriasis	1.19e-05	0.000148	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL6—psoriasis	1.17e-05	0.000146	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—TYK2—psoriasis	1.16e-05	0.000145	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.16e-05	0.000145	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.11e-05	0.000138	CbGpPWpGaD
Sulindac—ALB—Metabolism—CARM1—psoriasis	1.08e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—psoriasis	1.08e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Immune System—TYK2—psoriasis	1.06e-05	0.000132	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CAT—psoriasis	1.04e-05	0.000129	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—psoriasis	1.02e-05	0.000127	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.01e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCL8—psoriasis	1.01e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—psoriasis	1.01e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNG—psoriasis	9.94e-06	0.000124	CbGpPWpGaD
Sulindac—MAPK3—Disease—TYK2—psoriasis	9.8e-06	0.000122	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD4—psoriasis	9.6e-06	0.00012	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APOE—psoriasis	8.99e-06	0.000112	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—LEP—psoriasis	8.99e-06	0.000112	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—psoriasis	8.91e-06	0.000111	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD4—psoriasis	8.86e-06	0.000111	CbGpPWpGaD
Sulindac—MAPK3—Immune System—JUN—psoriasis	8.59e-06	0.000107	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NFKBIA—psoriasis	8.38e-06	0.000105	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NFKB1—psoriasis	8.27e-06	0.000103	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CAT—psoriasis	8.23e-06	0.000103	CbGpPWpGaD
Sulindac—PTGS2—Disease—HLA-A—psoriasis	8.18e-06	0.000102	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.12e-06	0.000101	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—APOE—psoriasis	8.05e-06	0.0001	CbGpPWpGaD
Sulindac—PTGS2—Disease—APOE—psoriasis	7.63e-06	9.52e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CARM1—psoriasis	7.57e-06	9.44e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—psoriasis	7.43e-06	9.27e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CAT—psoriasis	7.3e-06	9.11e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS2—psoriasis	7.11e-06	8.88e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.07e-06	8.83e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPARG—psoriasis	7.01e-06	8.75e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—psoriasis	6.88e-06	8.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TYK2—psoriasis	6.86e-06	8.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—psoriasis	6.86e-06	8.56e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CAT—psoriasis	6.66e-06	8.31e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—APOE—psoriasis	6.39e-06	7.98e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL8—psoriasis	5.97e-06	7.45e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TYK2—psoriasis	5.83e-06	7.27e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—psoriasis	5.68e-06	7.09e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—APOE—psoriasis	5.67e-06	7.08e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARG—psoriasis	5.57e-06	6.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUN—psoriasis	5.55e-06	6.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NFKB1—psoriasis	5.35e-06	6.67e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD4—psoriasis	5.27e-06	6.57e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—psoriasis	5.2e-06	6.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—psoriasis	5.19e-06	6.48e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—APOE—psoriasis	5.17e-06	6.45e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARG—psoriasis	4.94e-06	6.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—psoriasis	4.85e-06	6.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—psoriasis	4.8e-06	5.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—psoriasis	4.79e-06	5.98e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CAT—psoriasis	4.66e-06	5.81e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARG—psoriasis	4.5e-06	5.62e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—psoriasis	4.08e-06	5.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—psoriasis	3.67e-06	4.57e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOE—psoriasis	3.62e-06	4.51e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—psoriasis	3.36e-06	4.19e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARG—psoriasis	3.15e-06	3.93e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—psoriasis	2.85e-06	3.56e-05	CbGpPWpGaD
